Loading...
XNYSTAK
Market cap41bUSD
Dec 23, Last price  
13.17USD
1D
0.53%
1Q
-11.01%
Jan 2017
-36.62%
Name

Takeda Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XNYS:TAK chart
P/E
22.78
P/S
0.77
EPS
90.88
Div Yield, %
1,375.63%
Shrs. gr., 5y
-3.96%
Rev. gr., 5y
15.25%
Revenues
4.26t
+5.87%
1,122,960,000,0001,212,207,000,0001,305,167,000,0001,374,802,000,0001,538,336,000,0001,465,965,000,0001,419,385,000,0001,508,932,000,0001,557,267,000,0001,691,685,000,0001,777,824,000,0001,807,378,000,0001,732,051,000,0001,770,531,000,0002,097,224,000,0003,291,188,000,0003,197,812,000,0003,569,006,000,0004,027,478,000,0004,263,762,000,000
Net income
144.07b
-54.56%
277,438,000,000313,249,000,000335,805,000,000355,454,000,000234,385,000,000297,744,000,000247,868,000,000124,162,000,000131,244,000,000106,658,000,000-145,775,000,00080,166,000,000114,940,000,000186,886,000,000109,126,000,00044,241,000,000376,005,000,000230,059,000,000317,017,000,000144,067,000,000
CFO
716.34b
-26.69%
295,539,000,000373,575,000,000209,280,000,000292,495,000,000326,273,000,000381,168,000,000326,938,000,000336,570,000,000307,709,000,000148,335,000,000182,517,000,00025,491,000,000261,363,000,000377,854,000,000328,479,000,000669,752,000,0001,010,931,000,0001,123,105,000,000977,156,000,000716,344,000,000
Dividend
Mar 27, 20240.30055 USD/sh
Earnings
Jan 30, 2025

Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.
URL
https://www.takeda.com/
IPO date
May 16, 1949
Employees
49,095
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑032015‑03
Income
Revenues
4,263,762,000
5.87%
4,027,478,000
12.85%
3,569,006,000
11.61%
Cost of revenue
2,161,429,000
1,877,397,000
1,632,933,000
Unusual Expense (Income)
NOPBT
2,102,333,000
2,150,081,000
1,936,073,000
NOPBT Margin
49.31%
53.39%
54.25%
Operating Taxes
(91,406,000)
58,052,000
72,405,000
Tax Rate
2.70%
3.74%
NOPAT
2,193,739,000
2,092,029,000
1,863,668,000
Net income
144,067,000
-54.56%
317,017,000
37.80%
230,059,000
-38.81%
Dividends
(287,188,000)
(279,416,000)
(283,665,000)
Dividend yield
4.34%
4.09%
5.14%
Proceeds from repurchase of equity
(2,326,000)
(26,929,000)
(77,531,000)
BB yield
0.04%
0.39%
1.41%
Debt
Debt current
433,459,000
399,223,000
203,993,000
Long-term debt
5,583,363,000
4,882,197,000
4,552,779,000
Deferred revenue
Other long-term liabilities
491,752,000
658,670,000
755,836,000
Net debt
5,454,102,000
4,348,859,000
3,551,639,000
Cash flow
Cash from operating activities
716,344,000
977,156,000
1,123,105,000
CAPEX
(175,420,000)
(633,689,000)
(186,037,000)
Cash from investing activities
(463,862,000)
(607,102,000)
(198,125,000)
Cash from financing activities
(354,416,000)
(709,148,000)
(1,070,265,000)
FCF
1,593,324,000
1,969,514,000
1,734,785,000
Balance
Cash
472,889,000
553,704,000
875,000,000
Long term investments
89,831,000
378,857,000
330,133,000
Excess cash
349,531,900
731,187,100
1,026,682,700
Stockholders' equity
3,068,540,000
4,726,159,000
4,090,656,000
Invested Capital
12,879,616,100
10,873,225,900
9,557,169,300
ROIC
18.47%
20.48%
19.79%
ROCE
15.89%
18.11%
17.54%
EV
Common stock shares outstanding
1,580,343
1,569,872
1,577,169
Price
4,184.00
-3.82%
4,350.00
24.36%
3,498.00
-12.22%
Market cap
6,612,155,112
-3.17%
6,828,943,200
23.78%
5,516,937,162
-12.02%
EV
12,066,998,112
11,178,351,200
9,069,080,162
EBITDA
2,830,335,000
2,814,481,000
2,519,224,000
EV/EBITDA
4.26
3.97
3.60
Interest
119,535,000
169,698,000
166,607,000
Interest/NOPBT
5.69%
7.89%
8.61%